SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-284702
Filing Date
2019-11-05
Accepted
2019-11-05 16:07:11
Documents
14
Period of Report
2019-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d812240d8k.htm   iXBRL 8-K 29115
2 EX-99.1 d812240dex991.htm EX-99.1 46413
6 GRAPHIC g812240g1105091851805.jpg GRAPHIC 2091
  Complete submission text file 0001193125-19-284702.txt   213289

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gthx-20191105.xsd EX-101.SCH 3088
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gthx-20191105_lab.xml EX-101.LAB 18908
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gthx-20191105_pre.xml EX-101.PRE 11875
13 EXTRACTED XBRL INSTANCE DOCUMENT d812240d8k_htm.xml XML 3478
Mailing Address P. O. BOX # 110341 RESEARCH TRIANGLE PARK NC 27709
Business Address 79 T.W. ALEXANDER DRIVE 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 191193325
SIC: 2834 Pharmaceutical Preparations